bioRxivImmunologyPreprint
Highly potent anti-SARS-CoV-2 multivalent DARPin therapeutic candidates
M. Walser, S. Rothenberger, D. L. Hurdiss, A. Schlegel, V. Calabro, S. Fontaine, D. Villemagne, M. Paladino, T. Hospodarsch, A. Neculcea, A. Cornelius, P. Schildknecht, M. Matzner, M. Haenggi, M. Franchini, Y. Kaufmann, D. Schaible, I. Schlegel, C. Iss, T. Looser, S. Mangold, C. Herzog, D. Schiegg, C. Reichen, F. Radom, , Stittela
Abstract
Globally accessible therapeutics against SARS-CoV-2 are urgently needed. Here, we report the generation of the first anti-SARS-CoV-2 DARPin molecules with therapeutic potential as well as rapid large-scale production capabilities. Highly potent multivalent DARPin molecules with low picomolar virus neutralization efficacies were generated by molecular linkage of three different monovalent DARPin molecules. These multivalent DARPin molecules target various domains of the SARS-CoV-2 spike protein, thereby limiting possible viral escape. Cryo-EM analysis of individual monovalent DARPin molecules provided structural explanations for the mode of action. Analysis of the protective efficacy of one multivalent DARPin molecule in a hamster SARS-CoV-2 infection model demonstrated a significant reduction of pathogenesis. Taken together, the multivalent DARPin molecules reported here, one of which has entered clinical studies, constitute promising therapeutics against the COVID-19 pandemic.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Potent and pan-neutralization of SARS-CoV-2 variants of concern by DARPins
V. K. Chonira, Y.-D. Kwon, … Z. Chen·bioRxiv·May 30, 2022
- Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants
S. Rothenberger, D. L. Hurdiss, … Vassell·bioRxiv·Feb 3, 2021
- Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice
R. Salzer, J. J. Clark, … J. Lowe·bioRxiv·May 18, 2021
- Combinatorial Regimens Augment Drug Monotherapy for SARS-CoV-2 Clearance in Mice
I. Ullah, F. Escudie, … P. D. Uchil·bioRxiv·May 31, 2023
- Biparatopic sybody constructs neutralize SARS-CoV-2 variants of concern and mitigate emergence of drug resistance
J. D. Walter, C. A. J. Hutter, … M. A. Seeger·bioRxiv·Nov 10, 2020
- Development and characterization of a multimeric recombinant protein based on the spike protein receptor binding domain of SARS-CoV-2 that can neutralize virus infection
V. A. de Lima, R. d. S. Ferreira, … S. Schenkman·bioRxiv·Feb 15, 2023